AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Covid vaccine compensation could be given to thousands left 'disabled' by the AstraZeneca jab, it has emerged. Health Secretary Wes Streeting is understood to be considering plans to set up a ...

At the World Congress on Lung Cancer, this information was also presented by our collaborators, AstraZeneca team. This is data ... How do you understand the background to US Merck's decision ...

AstraZeneca will pay CSPC $100 million upfront, with potential for up to $1.92 billion in milestone payments. Airsupra Phase 3b trial shows significant reduction in severe asthma exacerbations ...

Oct 7 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd (1093.HK), opens new tab in an exclusive licence agreement to ...

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) ...

AstraZeneca said on Monday (Oct 7) it would pay up to US$1.92 billion to CSPC Pharmaceutical Group in an exclusive licence agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.

Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in ...

AstraZeneca has revealed it has expanded membership of its Senior Executive Team, which comes into effect immediately. The new changes include increased representation of the company’s ...

AstraZeneca Plc is licensing a drug from China’s CSPC Pharmaceutical Group Ltd that it hopes will treat high cholesterol, as the pharma company seeks to bolster its cardiovascular pipeline.